Considering Durvalumab outcomes by molecular subgroups, this study observed differences for Durvalumab as PFS among the different molecular subgroups in stage III unresectable NSCLC; patients with NSCLC with KRAS mutation had better ICI outcomes, in contrast to patients with other driver molecular alterations, such as EGFR mutations, BRAF mutations or ALK rearrangements. Here, EGFR is linked to non-small cell lung carcinoma.